CureVac NV and GlaxoSmithKline Plc released positive early data from laboratory testing of their second-generation Covid-19 vaccine, with signs the shot could also provide good protection against some variants of the virus.
Preclinical studies showed strong immune responses in rats, with significant neutralization of variants first discovered in the U.K., South Africa and Denmark, CureVac said in a statement Thursday. Human trials are expected to start in the third quarter.
